Abemaciclib: all 171 studies that test it

Page 1 of 2. Open to participants first (62), then studies with results posted, then the rest; newest registration first within each.

• Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingNCT07832227Phase 2
• A Study of Abemaciclib (LY2835219) in Healthy ParticipantsRecruitingNCT07818967Phase 1
• Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerEnrolling by invitationNCT07441369Phase 2
• Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and AbemaciclibNot yet recruitingNCT07428018Phase 2
• Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast CancerNot yet recruitingNCT07410559Phase 2
• Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast CancerNot yet recruitingNCT07292207Phase 2
• A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial CancerRecruitingNCT07209449Phase 2
• Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI TrialRecruitingNCT07191717Phase 2
• Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)RecruitingNCT07190443Phase 3
• A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerRecruitingNCT07100106Phase 1/2
• A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingNCT06835972Phase 1/2
• Using Tumor Models to Determine TreatmentsRecruitingNCT06813079Phase 2
• Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossRecruitingNCT06810544Phase 1/2
• The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant TreatmentNot yet recruitingNCT06810492Not applicable
• A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast CancerRecruitingNCT06678269Phase 1
• Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal CancerRecruitingNCT06654037Phase 1
• Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaRecruitingNCT06498648Phase 1/2
• Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingNCT06409390Phase 2
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3
• ALPINE: Maintenance Letrozole/AbemaciclibRecruitingNCT06366347Phase 2
• Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast CancerRecruitingNCT06365788Phase 2
• NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast CancerRecruitingNCT06259929Phase 2
• Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerRecruitingNCT06179303Phase 2
• Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)RecruitingNCT06169371Phase 4
• RADIANT: Pre-op Radiation With Abemaciclib and LetrozoleRecruitingNCT06139107Phase 1
• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingNCT06062498Phase 2
• A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for LiposarcomasRecruitingNCT06025747Phase 1
• A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerRecruitingNCT05999994Phase 2
• Abemaciclib in Newly Diagnosed Meningioma PatientsRecruitingNCT05940493Phase 2
• Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingNCT05933395Phase 2
• Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian CancerRecruitingNCT05872204Phase 2
• CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACCRecruitingNCT05774899Phase 1/2
• A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of MyelofibrosisRecruitingNCT05714072Phase 1
• VS-6766+Abema+Fulv in Met HR+/HER- BCRecruitingNCT05608252Phase 1/2
• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingNCT05524584Phase 2
• ETHAN - ET for Male BCRecruitingNCT05501704Phase 2
• Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With PalbociclibRecruitingNCT05464173Phase 1/2
• Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingNCT05386108Phase 1/2
• Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsRecruitingNCT05372640Phase 1
• Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect ManagementRecruitingNCT05362760Phase 4
• Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast CancerRecruitingNCT05305924Phase 2
• The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerRecruitingNCT05113537Phase 1/2
• Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast CancerRecruitingNCT05095207Phase 1/2
• Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi SarcomaRecruitingNCT04941274Phase 1/2
• SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain MetastasesRecruitingNCT04923542Phase 1/2
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingNCT04802759Phase 1/2
• Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical NeurofibromasRecruitingNCT04750928Phase 1/2
• Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerRecruitingNCT04633239Phase 1
• Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant AbemaciclibRecruitingNCT04614194Phase 2
• A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2
• Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial CancerRecruitingNCT04469764Phase 2
• Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.RecruitingNCT04305834Phase 2
• Study of eFT226 in Subjects With Selected Advanced Solid Tumor MalignanciesRecruitingNCT04092673Phase 1/2
• Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway AlterationRecruitingNCT04040205Phase 2
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2
• Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6RecruitingNCT03310879Phase 2
• INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)RecruitingNCT02977780Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
• Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingNCT02523014Phase 2
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerTerminatedNCT06630325Phase 2Results posted
• TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerActive, not recruitingNCT06001762Phase 2Results posted
• Neo-DAB: Darolutamide and Abemaciclib in Prostate CancerTerminatedNCT05617885Phase 1Results posted
• CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's SarcomaActive, not recruitingNCT05440786Phase 2Results posted
• Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisActive, not recruitingNCT05413304Phase 1Results posted
• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)Active, not recruitingNCT05288166Phase 3Results posted
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast CancerActive, not recruitingNCT05169567Phase 3Results posted
• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingNCT04975308Phase 3Results posted
• Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction CaCompletedNCT04921904Phase 1/2Results posted
• A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast CancerTerminatedNCT04752332Phase 3Results posted
• Abemaciclib With or Without Atezolizumab for mCRPCCompletedNCT04751929Phase 2Results posted
• A Study of Abemaciclib in Indian Women With Advanced Breast CancerCompletedNCT04707196Phase 4Results posted
• Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid CancerCompletedNCT04552769Phase 2Results posted
• A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.TerminatedNCT04534283Phase 2Results posted
• Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate CancerCompletedNCT04408924Phase 2Results posted
• Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast CancerTerminatedNCT04305236Phase 2Results posted
• Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer PatientsActive, not recruitingNCT04293393Phase 2Results posted
• Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)TerminatedNCT04169074Phase 2Results posted
• A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast CancerTerminatedNCT04031885Phase 4Results posted
• A Study to Evaluate Abemaciclib in Advanced Biliary Tract CarcinomaTerminatedNCT04003896Phase 2Results posted
• Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149TerminatedNCT03997448Phase 2Results posted
• Abemaciclib in Patients With OligodendrogliomaCompletedNCT03969706Phase 2Results posted
• Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerActive, not recruitingNCT03939897Phase 1Results posted
• Abemaciclib and Nivolumab for Subjects With Hepatocellular CarcinomaTerminatedNCT03781960Phase 2Results posted
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerActive, not recruitingNCT03706365Phase 2/3Results posted
• A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast CancerCompletedNCT03703466Phase 2Results posted
• Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedNCT03654833Phase 2Results posted
• Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial CancerCompletedNCT03643510Phase 2Results posted
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompletedNCT03280563Phase 1/2Results posted
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerActive, not recruitingNCT03155997Phase 3Results posted
• Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast CancerTerminatedNCT03130439Phase 2Results posted
• A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal AdenocarcinomaCompletedNCT02981342Phase 2Results posted
• A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic CancersCompletedNCT02919696Phase 1Results posted
• A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy ParticipantsCompletedNCT02884089Phase 1Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Breast CancerActive, not recruitingNCT02763566Phase 3Results posted
• A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the BodyCompletedNCT02688088Phase 1Results posted
• A Study of Abemaciclib in Healthy ParticipantsCompletedNCT02677844Phase 1Results posted
• A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast CancerCompletedNCT02675231Phase 2Results posted

← Abemaciclib overview